Clinical Trial Update: Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) [Phase 2]

View source ↗

Summary

Phase 2 ECZTRA 5 trial reports on vaccine responses in patients with atopic dermatitis treated with tralokinumab. Results were posted March 5, 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-03-05